Construction Begins, Financing Becomes the Make-or-Break for NXE

What happened

NexGen Energy has transitioned from regulatory review to active construction at Rook I, with the project now being built and the focus shifting to execution and financing, according to a Seeking Alpha article rating NXE a Buy. The article highlights that while Rook I's 239.6M lbs of probable reserves and high grades are compelling, the key risk is how NexGen secures the remaining project financing without excessively diluting shareholders or transferring value to lenders. Our prior WAIT stance centered on two binary catalysts: CNSC licence approval and binding project debt; with construction underway, the regulatory hurdle appears largely cleared, but financing is still unresolved. Management's recent actions, including a C$950M equity raise and physical uranium purchases, have strengthened the balance sheet but also introduced significant dilution and fixed obligations. The market's current ~US$7.3B valuation already implies successful build-out, leaving little room for financing disappointment.

Implication

The construction start reduces regulatory risk, but the stock's valuation leaves little margin for error, so discipline is required. NexGen must secure project debt on terms that limit further equity issuance; failure to do so could force significant dilution that undermines per-share value. The physical uranium position and high-coupon convertibles introduce complexity; if uranium prices weaken, the value of physical inventory may fall while convertibles remain a fixed claim. Investors should monitor for announcements of binding project finance packages and any updates on cost inflation; a debt package above US$1B with reasonable covenants would be a positive sign. Until such clarity emerges, a WAIT rating is appropriate; attractive entry would be below US$9, while trimming above US$14 remains prudent.

Thesis delta

The thesis has shifted from 'wait for regulatory and financing clarity' to 'wait for financing clarity only,' as construction has begun, suggesting CNSC approval has been obtained. The core risk now is whether NexGen can fund the remaining capex without excessive dilution or onerous terms, which will directly impact per-share value. Our WAIT rating is unchanged, but the focus of monitoring narrows to financing structure and cost control.